Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Income from Continuing Operations (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Income from Continuing Operations for 6 consecutive years, with 17142000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 150.98% to 17142000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 10547000.0 through Dec 2025, up 82.68% year-over-year, with the annual reading at 10547000.0 for FY2025, 82.72% up from the prior year.
  • Income from Continuing Operations hit 17142000.0 in Q4 2025 for Insight Molecular Diagnostics, up from 11048000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 17142000.0 in Q4 2025 to a low of 35691000.0 in Q4 2021.
  • Historically, Income from Continuing Operations has averaged 8950350.0 across 5 years, with a median of 8731000.0 in 2023.
  • Biggest YoY gain for Income from Continuing Operations was 274.6% in 2023; the steepest drop was 510.92% in 2023.
  • Year by year, Income from Continuing Operations stood at 35691000.0 in 2021, then soared by 66.33% to 12017000.0 in 2022, then plummeted by 34.63% to 16179000.0 in 2023, then plummeted by 107.84% to 33627000.0 in 2024, then soared by 150.98% to 17142000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for IMDX at 17142000.0 in Q4 2025, 11048000.0 in Q3 2025, and 9842000.0 in Q2 2025.